CSAM-SCAM Fundamentals. Cocaine Basics. Presentation provided by David C. Marsh MD CCSAM
|
|
- Aldous Hunter
- 5 years ago
- Views:
Transcription
1 CSAM-SCAM Fundamentals Cocaine Basics Presentation provided by David C. Marsh MD CCSAM
2
3 Chronic Illness Relapsing & Remitting in Course Genetic Predisposition Individual Choice a Factor Environmental Influence Potentially Fatal If Untreated Prevention Is Possible Properly Managed Can Lead Normal Life
4 Response Rates Drug and Alcohol Treatment 40-60% abstinent at 1 year (vary with drug) Best outcomes in those maintained in MMT or Participating in on-going Mutual Support Diabetes, Hypertension, Asthma 40-60% medication compliance <30% adherence with diet and risk reduction 50% symptoms require medical intervention within 1 year McLellan, Lewis, O Brien and Kleber (2000) JAMA 284:
5 Cocaine Effects Blocks Catecholamine Reuptake Dopamine, Noradrenalin, Adrenaline Euphoria Increased Energy Insomnia Anorexia Hypertension and Tachycardia Often combined with Alcohol to Prolong Effect
6 Cocaine Problems Multiple Organ Systems Damaged By Restriction of Blood Flow and Increased Metabolic Demand Myocardial Infarct or Arrhythmias Multiple Small Cerebral Infarcts Frequently Increased Sexual Risk Behaviour Risks Associated with Route of Use Smoking/Snorting Respiratory Damage Blood-Borne Illnesses passed by Sharing Implements Injection Local Sequelae including Infections Systemic Infections (Bacterial, Fungal, Viral)
7
8
9
10
11
12 # correct in 45 sec Stroop Task Improvement During Methamphetamine Abstinence Control (n = 141) * < 72 h n = 86 3 Months n = 19 *p < 0.05
13 Depression In Methamphetamine Abusers BDI Score Control scores = Weeks of Abstinence
14 Time (msec) % Correct Methamphetamine Abusers Show Impaired Attention * Reaction Time Accuracy *p<0.05
15 Cingulate Cortex In Methamphetamine Abuse Anterior Cingulate Posterior Cingulate
16 Glucose Metabolism (mg/100 g/min) Reaction Time Correlated To Angular Gyrus Metabolism In Methamphetamine Abusers CONTROL METHAMPHETAMINE r = r = 0.92 p < 0.05 Reaction Time (msec)
17 Emergency Management of Intoxication Stabilize Vital Signs (ABC s) Rule Out or Treat General Medical Conditions Diabetic Coma Subdural Haematoma Seizures Pneumonia Meningitis GI Bleeding
18 Subacute Management of Intoxication Provide a Reality Base Use names often State location repeatedly Non-Verbal Support Frequent, brief eye contact Relaxed posture Constant Subdued Lighting Never leave alone Always Check for Pregnancy Opiate Withdrawal in pregnancy can precipitate miscarriage
19 Pharmacological Treatment of Withdrawal (General Approaches) Symptomatic relief Cross-tolerance with longer half-life agent Less reinforcing and less dangerous mode of delivery of drug
20 Withdrawal Management and Treatment Treatment of Withdrawal is Not Treatment Patients with Substance Dependence requiring withdrawal management all require treatment Outpatient Counseling Intensive Day Treatment Intensive Residential Treatment Short-Term Residential Transitional Treatment Long-Term Residential Treatment Supportive Housing
21 Pharmacotherapy For Continuing Care (Broad Strategies) Pharmacological Avenues Aversion Decreased Appetite Decreased Reinforcement and Extinction Relapse Prevention Antagonist maintenance Long Acting Agonist Maintenance Prevent Complications In Face of Use
22 Oral Amphetamine Maintenance for Cocaine Dependence Pilot Study for 14 weeks (16 Pts. 60 mg/day; 14 Placebo) Treatment retention was equivalent between group Cocaine-positive urine samples treatment group declined from 94% to 56% compared no change in the placebo group (79% positive). treatment group reduced self-reported cocaine use (P= 0.02) reduced criminal activity (P=0.04) reduced cravings (P<0.01) reduced severity of cocaine dependence (P<0.01) no within-group improvements found in the placebo group Shearer J et al (2003) Addiction 98:
23 Pilot Studies of Medications for Cocaine Dependence in Heroin-Assisted Treatment Nuijten et al (2011) BMC Psychiatry 11:135
24 Topirimate for Cocaine Dependence Poor compliance with medication Limited benefit Nuijten et al (2015) Drug Alc Dep 138:177
25 Modafinil for Cocaine Dependence Poor compliance with medication Limited benefit unless high adherence Nuijten et al (2015) J Psychopharmacol 29:678
26 Fundamentals: Cannabis Dependence Summary Cocaine is highly reinforcing Dependence can be devastating to function but most users do not progress to dependence Treatment is challenging Relies on Psychosocial Interventions Medications should be primarily within context of clinical trials until proven effective
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationThe causes of misuse:
The Drug Misuse The causes of misuse: Availability of drugs. A vulnerable personality. Adverse social environment. Regular drug taking play a role. Determining misuse and dependence, it is unclear whether
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationMedication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.
Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationThe future of pharmacological treatment.
The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationPolysubstance Use & Medication-Assisted Treatment
Polysubstance Use & Medication-Assisted Treatment DSM-V eliminated polysubstance disorder, instead specifying each drug of abuse and dependence. Substance-use disorder is a combination of the two DSM-IV
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationMARRCH Minnesota Society of Addiction Medicine Presents. Addiction as a Brain Disease
MARRCH 2008 Minnesota Society of Addiction Medicine Presents Addiction as a Brain Disease Gavin Bart, MD Charles Reznikoff, MD Steven Fu, MD, MSCE David Frenz, MD, MS October 22, 2008 Schedule 10:00-12:00
More informationTREATMENT OF NICOTINE DEPENDENCE
TREATMENT OF NICOTINE DEPENDENCE Introduction Most commonly used substance the world over. Largest cause of preventable death worldwide. Leading causes of smoking related death Cardiovascular diseases
More informationPharmacotherapy for Substance Use Disorders
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health Services Agency 1400 Emeline Avenue Santa Cruz,
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationAddiction as a Neuropsychiatric Medical Condition
Addiction as a Neuropsychiatric Medical Condition Wilson M. Compton, M.D., M.P.E. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse 5 November 2009 Summary
More informationBASIC VOLUME. Elements of Drug Dependence Treatment
BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationNeurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP
Neurobiology of Addiction JeanAnne Johnson Talbert, DHA, APRN BC, FNP, CARN AP Disclosures This speaker has no conflicts of interest to disclose Objectives Define drug abuse and addiction Identify the
More informationNoel Schenk MD. Davis Behavioral Health
Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationMethamphetamine Abuse During Pregnancy
Methamphetamine Abuse During Pregnancy Robert Davis, MD / r.w.davismd@gmail.com ❶ Statistics ❷ Pregnancy Concerns ❸ Postpartum Concerns ❹ Basic Science ❺ Best Practice Guidelines ❻ Withdrawal ❼ Recovery
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationMethamphetamine & Cocaine Use Disorders
Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical
More informationBrief Intervention for Smoking Cessation. National Training Programme
Brief Intervention for Smoking Cessation National Training Programme Introduction Monitor tobacco use and prevention policies Protect people from tobacco smoke Offer help to quit tobacco use Warn about
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationThe Importance of Psychological Treatment and Behavioral Support
The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding
More informationAddiction Overview. Diane A. Rothon MD. Causes Consequences Treatments. Methadone/Buprenorphine 101 April 1, 2017
Addiction Overview Causes Consequences Treatments Methadone/Buprenorphine 101 April 1, 2017 Diane A. Rothon MD Why? would you listen to this presentation Review the definition and neurobiology of addiction
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationMethamphetamine & Cocaine Use Disorders
Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationWhat are Substance Use Disorders?
What are Substance Use Disorders? Sanchit Maruti, MD Michael Goedde, MD University of Vermont Medical Center 1 Disclosures } Drs. Maruti and Goedde receive compensation as consultants to the American Academy
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More informationMethamphetamine & Cocaine Use Disorders
Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical
More informationDoes the Use of Oral Amphetamines Reduce Cocaine Use in Cocaine-Dependent Individuals?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Does the Use of Oral Amphetamines Reduce
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationBiological Addictions Treatment. Psychology 470. Many Types of Approaches
Many Types of Approaches Biological Addictions Treatment Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides Detoxification approaches
More informationDRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT
DRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT Robert Graham, Staff Specialist in Addiction Medicine (with thanks to Dr Thao Lam and Pip Bowden) Drug Health, Western Sydney Local Health District Robert.Graham@health.nsw.gov.au
More informationUnderstanding Addiction: Why Can t Those Affected Just Say No?
Understanding Addiction: Why Can t Those Affected Just Say No? 1 The Stigma of Addiction There continues to be a stigma surrounding addiction even among health care workers. Consider the negative opinions
More informationInjectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP
Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report
More informationUnderstanding Addiction and Its Impact on the Brain. SDSMA Webinar Matthew Stanley, DO
Understanding Addiction and Its Impact on the Brain SDSMA Webinar Matthew Stanley, DO Estimated Economic Cost to Society Due to Substance Abuse and Addiction: Illegal drugs: Alcohol: Tobacco: $181 billion/year
More informationOPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY
OPIOID ADDICTION AND THE BRAIN MICHAEL NERNEY AND ASSOCIATES P.O. BOX 93 LONG LAKE, NY 12847-0093 518-624-5351 MCNERNEYLL@FRONTIERNET.NET A DISEASE OF THE BRAIN ASAM Primary chronic disease of the brain
More informationTREATMENT OF STIMULANT USE DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences TREATMENT OF STIMULANT USE DISORDERS Matt Iles-Shih, MD Addiction Psychiatry Fellow University Of Washington & VA
More informationQuality assurance in pharmacotherapy with methadone
Quality assurance in pharmacotherapy with methadone Dr. Emilis Subata Vilnius Centre for Addictive Disorders Psychiatry Clinic of Vilnius University emilis.subata@vplc.lt Outline of the presentation Introduction
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationIntro to Concurrent Disorders
CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationTrigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module VI Counseling Buprenorphine Patients Myths About the Use of Medication in Recovery! Patients are still addicted!
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationPage 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationPharmacologic Interventions for. Addictions
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationOpioids and Opioid Addiction: Practical Management Approaches
Opioids and Opioid Addiction: Practical Management Approaches Yngvild Olsen, MD, MPH Medical Director Institutes for Behavior Resources Inc/REACH Health Services Conflict of Interest No financial or advisory
More informationLong term treatment for opioid dependence Antagonist therapy
Long term treatment for opioid dependence Antagonist therapy Treatment of Opioid Dependence Antagonist treatment Naltrexone Naltrexone (NTX) synthesized in 1965 Eliminate drug carving and prevent relapse
More informationPharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations
Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Dr. Ajeet Sidana Department of Psychiatry Government Medical College & Hospital Chandigarh Scope of Presentation
More informationADHD and Substance Use Disorders: An Intoxicating Combination
ADHD and Substance Use Disorders: An Intoxicating Combination Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Director, Center for Addiction Medicine Massachusetts General Hospital
More informationTHE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA
THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED
More informationEvidence-Based Practice: Psychosocial Interventions
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio Talk Outline What is an evidence-based practice?
More informationThaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs
Thaddeus Ulzen MD FRCP(C)FAPA FCGP Professor & Chair, Department of Psychiatry and Behavioral Medicine, Associate Dean for Academic Affairs CCHS/University of Alabama School of Medicine Assessment History
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationNational Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says
National Institute on Drug Abuse (NIDA) Understanding Drug Abuse and Addiction: What Science Says Last Updated February 2016 https://www.drugabuse.gov 1 Table of Contents Understanding Drug Abuse and Addiction:
More informationTOOL 1: QUESTIONS BY ASAM DIMENSIONS
TOOL 1: QUESTIONS BY ASAM DIMENSIONS The following tool highlights specific questions that should be asked of the patient for each ASAM dimension. Name Date of Birth Date of Interview Address Referred
More information8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy
Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationExploring Barriers & Solutions in Facilitating Detox
Exploring Barriers & Solutions in Facilitating Detox Dr Brion Sweeney 8 th April 2008 Background Everyone is an expert Abstinence Based Programmes Harm Reduction Approaches Remissions, Relapses and Interventions
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationSubstance Use Disorders. A Major Problem. Defining Addiction 2/24/2009. Lifetime rates of alcoholism estimated at 13.4 %
Substance Use Disorders A Major Problem Lifetime rates of alcoholism estimated at 13.4 % Rates of drug abuse estimated at 6% Marijuana is most frequent Approximately 600,000 deaths each year from substance
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationThe role of behavioral interventions in buprenorphine treatment of opioid use disorders
The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationThe Sinclair Method (TSM) for the Treatment of Alcoholism. Clinical Research Findings and Best Protocol for Success Updated 2014
Information for Medical & Treatment Professionals The Sinclair Method (TSM) for the Treatment of Alcoholism Clinical Research Findings and Best Protocol for Success Updated 2014 "One medication, naltrexone,
More informationMany drugs of abuse are illegal drugs. Possessing, using, buying, or selling these drugs is illegal for people of any age.
1 Chapter 12 Section 1 Objectives List six ways illegal drug use can be dangerous. State five reasons a person might try illegal drugs. Identify the reason drug abuse is especially dangerous to teens.
More informationImproving Outcomes in Methadone Treatment
Improving Outcomes in Methadone Treatment Cognitive/Behavioral Treatment Contingency Management Michael J. McCann, MA Matrix Institute on Addictions COMP Symposium September 11, 2007 Overview of Presentation
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationMedical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine
Medical Interventions for Addiction in Primary Care Settings R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine March 23, 2010 NIH Consensus on Drug Treatment Drug Addiction
More information2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders
The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,
More informationTreatment of Methamphetamine Dependence: Does Treatment Work?
Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationThe National Methamphetamine Symposium
The National Methamphetamine Symposium Making Research Work in Practice 12 May 2015 Arts Centre, Melbourne Physical and psychological effects of methamphetamine use Amanda Baker PhD National Centre for
More informationMary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit
Mary Ann Ferguson,Pharmacist St Josephs Health Care Concurrent Disorders Inpatient Unit Fergusom@stjoes.ca Medication should be considered as part of the treatment plan for addictions/substance use disorders:
More informationAdult 65D-30 Intervention ASAM Level.05 DIMENSIONS Circle all items in each dimension that apply to the client. ADMISSION CRITERIA
Adult 65D-30 Intervention ASAM Level.05 ADMISSION CRITERIA Place a check in the yes or no box that indicates validation or lack ASAM Requirements Withdrawal and of validation for placement into this level
More informationMedical Management of Substance Use Disorders: Does research translate to clinical practice
Medical Management of Substance Use Disorders: Does research translate to clinical practice Ashwin A Patkar, MD Professor of Psychiatry & Community & Family Medicine Duke University Medical Center Durham,
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More information